Table of Contents Table of Contents
Previous Page  373 / 812 Next Page
Information
Show Menu
Previous Page 373 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S369

Introduction

Aripiprazole is the firstborn of the new dynasty

of antipsychotic called third generation or neuromodulator of

dopamine-serotonin system. It has proven to be an effective and

well-tolerated antipsychotic. Dual Pathology represents the pres-

ence of comorbidity between mental illness and substance use

disorders. It is an under-diagnosed problem and it is increasing

frequency.

Objectives

The aim of this study was to determine and describe

the clinical profile of the patients admitted to the Dual Pathology

Unit (UPD) at TheMontalvos Hospital (Part of Salamanca University

Teaching Hospital, Spain) treated with oral Aripiprazole.

Methods

Descriptive, observational, retrospective study of a

sample of patients admitted to the UPD to which oral aripiprazole

was prescribed during hospitalization. A number of sociodemo-

graphic, clinical, and treatment-related variables are described.

Results

From a sample of 25 patients and according to DSM-5

criteria (APA, 2013) main diagnoses were: 14 cases of substance-

induced psychotic disorder, 3 cases of schizophrenia; 3 cases of

schizoaffective disorder; 2 cases of bipolar disorder; 1 case of

schizophreniform disorder; 1 case of borderline personality disor-

der; 1 case of personality syndrome. Themost used drugs before the

admittance were cocaine, cannabis and opioids. The average dose

of aripiprazole was 9mg and no side effects or drug interactions

were reported.

Conclusions

Apart from its well known efficacy in treament

of psychosis, oral aripiprazole may be a first line treatment for

Dual diagnosis patients, specially those with problems of non-

compliance, due to high level prolactine side effects.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1045

EV61

Personality disorders: Which

personality features lead to a

comorbid substance use disorder?

A. Lombardi

, A. R

ossi , C. Gramaglia , L. Girardi , P. Zeppegno

Università del Piemonte Orientale, Traslational Medicine, Novara,

Italy

Corresponding author.

Introduction

Dual Diagnosis (DD) refers to coexistence of a psy-

chiatric disorder, which is often a Personality Disorder (PD), and

a Substance Use Disorder (SUD). Despite DD is a topic of interest

in recent years, few studies have focused on the temperament and

character traits of PD patients with or without a comorbid SUD.

Anyhow, the assessment of personality traits may be helpful to

understand the relation among psychiatric disorder, drug use and

environment in patients with addictive behaviors.

Aims

The aim of this study is to compare two subgroups of PD

patients, with and without a comorbid SUD. Sociodemographic,

clinical and personality profile, as assessed with the Temperament

and Character Inventory, will be compared.

Methods

We are recruiting patients with a PD diagnosis refer-

ring either the psychiatry ward or outpatient service of the AOU

“Maggiore della Carità”, Novara, Italy; secondly, wewill group them

according to the presence/absence of SUD. Cloninger’s TCI-R will

be administered together with a structured interview to gather

sociodemographic and clinical information.

Results

Data collection is ongoing; we expect to find a different

personality profile in PD and DD Patients.

Conclusions

Temperament, which is the biological part of the per-

sonality, seems to have an important role in addictive behavior;

therefore assessing the personality traits of DD patients can help

to improve the differential diagnosis and to establish strategies

for treatment and prevention. In particular, sensation seeking and

impulsivity are temperamental characteristics that may favor SUD

in patients with psychiatric disorders.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1046

EV62

Video game addiction: Providing

evidence for Internet gaming disorder

through a systematic review of

clinical studies

O. Lopez-Fernandez

1 ,

, D. Kuss

2

, H. Pontes

2

, M. Griffiths

2

1

IPSY, PSP, Louvain-la-neuve, Belgium

2

IGRU, Division of Psychology, Nottingham, United Kingdom

Corresponding author.

Introduction

The American Psychiatric Association introduced in

Internet Gaming Disorder (IGD) in the appendix as a tentative dis-

order in the last edition of the Diagnostic and Statistical Manual of

Mental Disorders. However, currently no systematic review exists

about excessive gaming viewed from a clinical perspective.

Objectives and aims

To review clinical studies on gaming addic-

tion in order to ascertain characteristics of both clinical and

research studies to provide retrospective evidence in relation with

the proposed IGD classification (including criteria, measures and

therapies).

Methods

A systematic literature reviewof studies published from

1980 to 2015 has been conducted using three major psychology

databases: Academic Search Complete, PsycInfo, and PsycArticles.

A total of 5033 results from peer-reviewed journals were obtained,

where 32 were identified as empirical clinical papers focused on

gaming addiction.

Results

The clinical research studies on gaming identified were

published between 1998 and 2015, most of which included

patient samples. Categorizations identified in the research papers

included: (i) patients’ characteristics (e.g., socio-demographics), (ii)

criteria and measures used (e.g., scales to diagnose), (iii) types of

gaming problems (e.g., game genre), (iv) and treatments (e.g., type

of therapy).

Conclusions

Findings will be discussed against the background

of the controversial IGD diagnostic criteria proposed in the DSM-5

in order to assess the extent to which previously published clini-

cal knowledge matched the current proposal for including gaming

addiction as behavioral addiction in the next diagnostic manual.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1047

EV63

Cannabinoid hyperemesis syndrome

S. López-Romeo

, G. Ledesma-Iparraguirre

Parc Sanitari Sant Joan de Déu, Psychiatry, Barcelona, Spain

Corresponding author.

Case report

A 25-year-old man was attended in multiple times at

Emergency Department by referring abdominal pain and vomiting.

No organic disease was found and he was referred to Psychiatric

Emergency to assess him. He had history of cannabis use (4–5

times/day) during last 5 years. He referred recurrent episodes of

abdominal pain and vomiting since 4 years ago, he had found

that having hot showers alleviate his symptoms. Urine screening

was positive for THC and negative for other drugs. In results of

blood tests, abdominal X-ray, abdominal ultrasonography, abdom-

inal tomography and fibrogastroscopy didn’t find any abnormality.

Hewas diagnosed fromsuffering a somatoformdisorder. Treatment

with Setraline 50mg/day was prescribed and cannabis abstinence

was recommended. He was referred to Mental Health outpatient

service. He maintained cannabis abstinence for 1 month and some

symptoms disappeared. However, 2 months later, he relapsed in